Fig. 1: The CPT score based on CD39, PD-L1 and TMB predicts therapeutic efficacy of PD-L1 blockade in MIBC. | British Journal of Cancer

Fig. 1: The CPT score based on CD39, PD-L1 and TMB predicts therapeutic efficacy of PD-L1 blockade in MIBC.

From: Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients

Fig. 1

a Kaplan–Meier curve for OS by CD39 expression for patients treated with atezolizumab in IMvigor210 cohort. Log-rank test was performed. b PD-L1, TMB and CD39 expression were independent predictive factors for PD-L1 blockade. c Kaplan–Meier curve for OS by CPT score for patients treated with atezolizumab in IMvigor210 cohort. Log-rank test was performed. d Clinical response to PD-L1 blockade by CPT score in IMvigor210 cohort. Chi-square test was performed (***P < 0.001). OS overall survival, HR hazard ratio, CI confidence interval, PD-L1 programmed death ligand 1, IC0 PD-L1 expression on <1% of tumour-infiltrating immune cells, IC1 PD-L1 expression on 1–<5% of tumour-infiltrating immune cells, IC2+ PD-L1 expression on ≥5% of tumour-infiltrating immune cells, TMB tumour mutation burden, CR complete response, PR partial response, SD stable disease, PD progressive disease.

Back to article page